Genetic counselling, BRCA1/2 status and clinico-pathologic characteristics of patients with ovarian cancer before 50 years of age
References
- Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 104: 2807-16. 10.1038/bjc.2012.483
- Brozek I, Ochman K, Debniak J, Morzuch L, Ratajska M, Stepnowska M, et al. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008; 108: 433-7. 10.1016/j.ygyno.2007.09.035
- Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol 2009; 3: 138-50. 10.1016/j.molonc.2009.02.001
- Soegaard M, Kruger Kjaer S, Cox M, Wozniak E, H
$\mathop {\acute\oslash}$ $\mathop {\acute\oslash}$ - Trainer AH, Meiser B, Watts K, Mitchell G, Tucker K, Friedlander M. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Int J Gynecol Cancer 2010; 20: 704-16. 10.1111/IGC.0b013e3181dbd1a5
- Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011; 121: 353-7. 10.1016/j. ygyno.2011.01.020
- Krajc M, De Greve J, Goelen G, Teugels E. BRCA2 founder mutation in Slovenian breast cancer families. Eur J Hum Genet 2002, 10: 879-82. 10.1038/sj.ejhg.5200886
- Krajc M, Teugels E, Žgajnar J, Goelen G, Bešić N, Novaković S, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. BMC Med Genet 2008; 9: 83. 10.1186/1471-2350-9-83
- Stegel V, Krajc M, Žgajnar J, Teugels E, De Greve J, Hočevar M, et al. The occurence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population. BMC Med Genet 2011, 12: 9. 10.1186/1471-2350-12-9
- Cvelbar M, Hočevar M, Vidmar G, Teugels E. BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. Neoplasma 2011; 58: 198-204. 10.4149/neo_2011_03_198
- Novaković S, Milatović M, Cerkovnik P, Stegel V, Krajc M, Hočevar M, et al. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int J Oncol 2012, 41: 1619-27. 10.3892/ ijo.2012.1595
- Krajc M, Zadnik V, Novaković S, Stegel V, Teugels E, Bešić N, et al. Geographical distribution of Slovenian BRCA1/2 families according to family origin: implications for genetic screening. Clin Genet 2014; 85: 59-63. 10.1111/cge.12119
- Bešić N, Cernivc B, de Gréve J, Lokar K, Krajc M, Novaković S, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. Genet Test 2008; 12: 203-9. 10.1089/gte.2007.0071
- Krajc M, Blatnik A, Stegel V, Cerkovnik P, Škof E, Novaković S. BRCA status in ovarian cancer patients predicts therapeutic approach – first results. In: Writzl K, Teran N, Maver A, editors. 6thsymposium of the Slovenian Association of Medical Genetics. Gene editing technology: applications and societal implications. Book of abstracts; 2016 Apr 22; Ljubljana, Slovenia. Ljubljana: Slovenian Association of Medical Genetics, Slovenian Medical Association; 2016. p. 19.
- Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654-63. 10.1200/ JCO.2011.39.8545
- Girolimetti G., Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, et al. BRCA-associated ovarian cancer: From molecular genetics to risk management. Biomed Res Int 2014; 2014: 787143. 10.1155/2014/787143
- Lakhani SR, Manek S, Penault-Lorca F, Flanagan A, Arnout L, Merrett S, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10: 2473-81. 10.1158/1078-0432.CCR-1029-3
- Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am, Deck D, et al. Patients with double-primary tumors in the breast and ovary – clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 2000; 79: 74-8. 10.1006/ gyno.2000.5895
- Schorge JO, Mahoney NM, Miller DS, Coleman RL, Muller CY, Euhus DM, et al. Germline BRCA1-2 mutations in Non-Ashkenazi families with double primary breast and ovarian cancer. Gynecol Oncol 2001; 83: 383-7. 10.1006/gyno.2001.6431
- Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev 2012; 21: 134-47. 10.1158/1055-9965.EPI-11-0775
- Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283: 2260-5.
- Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathologic features. Virchows Arch 2012; 460: 237-49. 10.1007/s00428-012-1203-5
- Rakar S, Štolfa A, Kovačič J. Ovarijski karcinom: današnje stanje in Perspektive. Zdrav Vestn 1994; 63: 569-71.
- Cvelbar M, Kralj B. Zgodnje odkrivanje epitelnega karcinoma jajčnika. Zdrav Vestn 2001; 81-4.
- Schwartz DR, Kardia SLR, Shedden KA, Kuick R, Michailidis G, Taylor JMG, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002; 62: 4722-9.
- Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-208. 10.1158/1078-0432
- Wickramanayake A, Bernier G, Pennil C, Casadei S, Agnew KJ, Stray SM, et al. Loss of function germline mutations in RAD51D in women with ovarian carcinoma. Gynecol Oncol 2012; 127: 552-5. 10.1016/j.ygyno.2012.09.009
Language: English
Page range: 187 - 194
Submitted on: Nov 1, 2016
Accepted on: Jan 13, 2017
Published on: Mar 16, 2017
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2017 Mirjam Cvelbar, Marko Hocevar, Srdjan Novakovic, Vida Stegel, Andraz Perhavec, Mateja Krajc, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.